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Introduction: Elevated brain potassium levels ([K+]) are associated with neuronal damage in experimental models.
The role of brain extracellular [K+] in patients with poor-grade aneurysmal subarachnoid hemorrhage (aSAH) and its
association with hemorrhage load, metabolic dysfunction and outcome has not been studied so far.
Methods: Cerebral microdialysis (CMD) samples from 28 poor grade aSAH patients were analyzed for CMD [K+]
for 12 consecutive days after ictus, and time-matched to brain metabolic and hemodynamic parameters as well
as corresponding plasma [K+]. Statistical analysis was performed using a generalized estimating equation with an
autoregressive function to handle repeated observations of an individual patient.
Results: CMD [K+] did not correlate with plasma [K+] (Spearman’s ρ = 0.114, P = 0.109). Higher CMD [K+] was associated
with the presence of intracerebral hematoma on admission head computed tomography, CMD lactate/pyruvate ratio >40
and CMD lactate >4 mmol/L (P< 0.05). In vitro retrodialysis data suggest that high CMD [K+] was of brain cellular origin.
Higher CMD [K+] was significantly associated with poor 3-month outcome, even after adjusting for age and disease severity
(P< 0.01).
Conclusions: The results of this pilot study suggest that brain extracellular [K+] may serve as a biomarker for brain tissue
injury in poor-grade aSAH patients. Further studies are needed to elucidate the relevance of brain interstitial K+ levels in the
pathophysiology of secondary brain injury after aSAH.Introduction
Maintenance of brain ion homeostasis is critical for synap-
tic transmission and proper functioning of the neuron-glia
signalling network [1]. After aneurysmal subarachnoid
hemorrhage (aSAH), several mechanisms may contribute
to transient or prolonged accumulation of brain extra-
cellular potassium (K+): erythrocytolysis [2], unspecific
membrane breakdown due to parenchymal injury
[3-5], dysfunction of Na+/K+ pump [1,6-8] and, on the* Correspondence: raimund.helbok@uki.at
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unless otherwise stated.one hand, compromised glial buffering [9,10], on the
other hand, activation of neuronal ATP–sensitive, or G
protein–dependent, calcium-sensitive K+ channels due to
energy failure [11,12]. During aSAH, both blood com-
pounds [3,13] and ischemia [14] may induce cortical
spreading depolarization (CSD). CSD leads to a transi-
ent or sustained increase of brain extracellular K+ con-
centration ([K+]) up to 60 mmol/L, far beyond its
physiological range [8]. Notably, ictal epileptic events
and spreading depolarization are the only events in the
brain during which extracellular [K+] reaches such high
levels [12,14]. For comparison, during ictal epileptic
events, extracellular [K+] increases from only 3 to
12 mmol/L [15].
In patients with severe traumatic brain injury (TBI),
higher brain extracellular [K+] was correlated withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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glutamate levels, increased intracranial pressure (ICP)
and poor functional outcome, thus supporting a rela-
tionship between higher brain extracellular [K+] and
dysfunction and/or damage of the brain parenchyma
[5]. Derangement of plasma [K+] is associated with
muscle weakness and cardiac arrhythmia as well as, to
a lesser degree, cerebral symptoms such as lethargy, ir-
ritability, confusion and coma. Neurological symptoms
are more likely related to concomitant Na+ and acid-
base disturbances, suggesting that brain extracellular
[K+] may be independent of plasma K+ levels. The re-
sults of studies done in animal models have shown that
the disrupted blood–brain barrier can be open to large
molecules, but can maintain the stability of the extra-
cellular [K+] [16]. Little is known about the relation-
ship between plasma and cerebral extracellular [K+]
after acute brain injury in humans.
In this pilot study, we investigated the relationship
between brain extracellular [K+] and plasma [K+] and
the association of high CMD [K+] with brain metabolic
and hemodynamic parameters and functional outcome
in poor-grade aSAH patients.Material and methods
Study population
Data were recorded prospectively for 28 consecutive aSAH
patients who underwent brain multimodal neuromonitor-
ing, including ICP, brain tissue oxygen tension (PbtO2) and
cerebral microdialysis, between September 2010 and
October 2012, and the CMD samples were retrospectively
analyzed for CMD [K+]. The following institutional criteria
for invasive neuromonitoring were applied: (1) Glasgow
Coma Scale (GCS) score ≤8 upon admission or deterior-
ation to a GCS score ≤8 during hospitalization, (2) low like-
lihood of regaining consciousness within the next 48 hours,
(3) high likelihood of surviving at least 48 hours and (4)
age > = 18 years. The study was approved by the Independ-
ent Ethics Committee of Innsbruck Medical University
(UN3898 285/4.8) and was carried out in adherence to the
ethical conduct of clinical research involving critically ill
patients issued by the Austrian Federal Office for Safety
in Health Care. In line with this, if incapacity as a result
of the critical illness precluded standard informed con-
sent, deferred consent was required according to the
Independent Ethics Committee approval. After regain-
ing the ability to consent, patients were informed with-
out delay and asked for their consent for further
participation in the study. In the case of persistent incap-
acity, proxy consent was obtained according to Austrian
law. Additionally, the public on the research site was
informed about the study by notice on the bulletin board
at the neurological ICU.General management
Patient care was carried out in adherence to the
guidelines of the American Heart Association for
management of aSAH [17]. Hemodynamic and fluid
management were targeted to achieve a cerebral per-
fusion pressure (CPP) >70 mmHg. The target for
intracranial pressure (ICP) was <20 mmHg. Patients
were treated to maintain euvolemia, normonatremia and
normokalemia, depending on disease severity and left at
the discretion of the attending neurintensivist.
Cerebral microdialysate and plasma potassium
measurements
Three consecutive CMD samples were pooled to ob-
tain >40 μl for analysis of CMD [K+] using the i-STAT
system and i-STAT EC8+ cartridges (Abbott Point of
Care, Princeton, NJ, USA) [18]. Plasma electrolytes were
measured using the ABL800 FLEX blood gas analyzer
(Radiometer Medical, Brønshøj, Denmark).
Monitoring and data acquisition
Neuromonitoring probes were placed, through a sub-
cutaneous tunnel or using a triple-lumen bolt, into the
white matter at greatest risk for secondary brain injury,
which we defined as brain tissue with the highest prob-
ability for damage due to delayed cerebral infarction.
The location of the microdialysis catheter was confirmed
by head CT scan, usually obtained within 24 hours after
surgery, and graded to distinguish radiologically “nor-
mal” from “perilesional” tissue (CMD probe <1 cm dis-
tant from a hematoma or hypodensity) or “intralesional”
tissue (within a hemorrhagic or ischemic lesion). CMD was
performed using a 100 kDa cutoff microdialysis catheter
(CMA-71; M Dialysis, Stockholm, Sweden), and perfusion
fluid (Na+ 147 mmol/L, CaCl2+ 1.2 mmol/L, MgCl2+
0.9 mmol/L, KCl+ 2.7 mmol/L (CNS perfusion fluid); M
Dialysis) was pumped at a flow rate of 0.3 μl/min.
Hourly samples were analyzed (CMA 600 and ISCUS flex,
M Dialysis AB, Stockholm, Sweden) for interstitial glu-
cose, pyruvate, lactate and glutamate concentrations and
frozen at −80°C. ICP was measured with an intraparench-
ymal probe (NEUROVENT; RAUMEDIC, Helmbrechts,
Germany), and PbtO2 was measured using a Clark-type
probe (LICOX; Integra LifeSciences, Plainsboro, NJ,
USA). In weekly meetings of the study team (RH, BP, RB,
MF, AS and ES), disease and treatment complications
were evaluated as part of the development of an ongoing
prospective database. Delayed cerebral infarction was de-
fined as a newly appearing infarction found on follow-up
brain CT scans and judged by an independent radiologist
to be attributable to vasospasm. Pneumonia was defined
as chest X-ray infiltrate plus elevated systemic inflamma-
tory parameters. Survival and functional outcome were
evaluated prospectively with the modified Rankin Scale
Table 1 Patient characteristics (N = 28)a
Clinical characteristics Data
Age (yr) 56 (47 to 68)






Admission APACHE II score 18 (14 to 21)
Admission radiological characteristics





IVH sum score 5 (0 to 9)
Intracerebral hematoma 13 (46%)
Aneurysm size >10 mm 8 (29%)
Generalized cerebral edema 11 (39%)
Surgical procedures/interventions
Clipping 20 (71%)
Hydrocephalus requiring CSF diversion 22 (79%)
Hyperosmolar therapy 14 (50%)
Complications
Pneumonia 21 (75%)
Delayed cerebral infarction 6 (21%)
Outcome characteristics
Length of hospital stay (days) 40 (27 to 50)
3-month mRS score
0 to 1 5 (17.9%)




aAPACHE II = Acute Physiology and Chronic Health Evaluation II; CSF = Cerebrospinal
fluid; H&H=Hunt and Hess; IVH = Intraventricular hemorrhage; mRS =modified
Rankin Scale. Data shown are n (%) for categorical variables and median (IQR) for
continuous variables.
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ducted by a study nurse blinded to neuromonitoring data.
Poor neurological outcome was defined as mRS score >4
(severe disability or death). An electronic patient data
management system (Centricity Clinical Notification Sys-
tem with Centricity Critical Care 7.0 software; GE Health-
care, Little Chalfont, UK) was used to acquire digital data
for blood pressure, ICP, CPP and PbtO2 every 3 minutes
from the monitoring device (CARESCAPE Monitor B650;
GE Healthcare). Brain tissue hypoxia was defined as
PbtO2 < 20 mmHg, based on previous studies demon-
strating a higher risk of metabolic distress and poor
outcome below this threshold value [19,20]. Low CPP
was considered ≤70 mmHg in accordance with data
showing an association of this threshold with metabolic
crisis (CMD lactate/pyruvate ratio (LPR) >40 and CMD
glucose <0.7 mmol/L) and brain tissue hypoxia [19]. Meta-
bolic distress was defined as CMD LPR >40. We also
categorized data for CMD LPR >25, deeming it an early
warning sign of metabolic distress [21,22]. High CMD
lactate, high CMD glutamate and low CMD pyruvate
were considered to be present when measurements
>4 mmol/L [20,21], >10 μmol/L [22] and <119 μmol/L
[20,23], respectively, were observed.
Statistical analysis
Data for CPP, ICP, PbtO2, plasma [K
+] and CMD metab-
olites were time-matched to the 3-hour period of the
pooled sample and averaged to the corresponding CMD
[K+] analysis. Continuous variables were dichotomized
based on clinical cutoff points or median values. Univar-
iate and multivariate comparisons of pooled data were
performed using a generalized linear model with a bino-
mial distribution and logit link function. The model was
extended by using generalized estimating equations with
the autoregressive matrix of the first order to handle
repeated observations of the same patient [24].
The percentage of CMD samples with CMD [K+] above
the median was calculated for each patient, to assess
differences between outcome groups (Mann–Whitney U
test). For correlation analyses, Spearman’s ρ was used.
The results are reported as medians with IQRs unless
otherwise specified. P < 0.05 was considered statistically
significant. SPSS 21 software (SPSS Inc, Chicago, IL,
USA) was used for data analysis.
In vitro potassium measurements
In vitro analysis was performed using a 100 kDa cutoff CMD
catheter (CMA-71) at a constant flow rate of 0.3 μl/min to
determine the relative recovery rate. The relative recovery
rate was defined as the [K+] level in the microdialysate
divided by [K+] in three different K+ dilutions (low, medium
and high). The K+ dilution was created using concen-
trated K+ (1 mmol/ml K+) diluted by isotonic NaCl toobtain low (2.2 mmol/L), medium (4.3 mmol/L) and
high (9.0 mmol/L) K+ dilutions. The tip of the CMD
catheter was then inserted into the K+ dilution. Micro-
dialysate was collected hourly and pooled over the
course of 3 hours for analysis using the method described
above. [K+] in the microdialysate was 9.0 ± 0 mmol/L (SD)
in the high [K+] dilution, 4.2 ± 0.07 mmol/L (SD) in the
medium [K+] dilution and 2.0 ± 0.14 mmol/L (SD) in the
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tive in vitro recovery rates of 100% in the presence of high
[K+], 98% in the presence of medium [K+] and 91% in the
presence of low [K+]. In order to determine the accuracy
of this method, we double-analyzed the same [K+] dilu-
tions at 3 hours, 6 hours and 9 hours after the beginning
of in vitro microdialysis, which revealed identical [K+] at all
time points.Results
Study population
Twenty-eight aSAH patients were included in our ana-
lysis (Table 1). Neuromonitoring was initiated on day 1
after ictus (1 to 2 days). The CMD catheter location was
in radiologically normal tissue in 15 patients (54%) and
in perilesional tissue in 13 patients (46%). Four patients
died during hospitalization due to brain herniation (n = 2),
mesenteric ischemia (n = 1) or septic shock (n = 1). One of
these patients died during the neuromonitoring period on
the tenth day after ictus.Cerebral microdialysate and plasma potassium
concentrations
Admission plasma [K+] was 3.7 mmol/L (3.4 to 4 mmol/L)
and increased only slightly during hospitalization to
3.9 mmol/L (3.7 to 4.1 mmol/L). Median CMD [K+]
was 3 mmol/L (2.7 to 3.2 mmol/L). Plasma [K+] did not
correlate with CMD [K+] (Spearman’s ρ = 0.114; P = 0.109)
(Figure 1).Figure 1 Correlation between potassium concentrations in plasma and c
CMD= Cerebral microdialysate.Cerebral microdialysate, plasma potassium and brain
homeostasis
CMD [K+] was positively correlated with CMD lactate levels
(Spearman’s ρ 0.453; P < 0.0001), CMD LPR (Spearman’s ρ=
0.368; P < 0.0001) andCMDglutamate levels (Spearman’s ρ=
0.355; P= 0.0002), whereas the strongest correlation was
found during days 7 to 12 (CMD lactate: Spearman’s ρ=
0.489, P < 0.0001; CMD LPR ρ= 0.006; Spearman’s ρ= 0.463;
CMD glutamate ρ= 0.000; Spearman’s ρ= 0.481) and in pa-
tients with delayed cerebral infarction (CMD glutamate ρ=
0.005; Spearman’s ρ= 0.840, P < 0.01; CMD lactate ρ= 0.003
Spearman’s ρ= 0.773, P < 0.01). Univariate analysis revealed
an association between higher CMD [K+] and CMD LPR >25,
CMD LPR > 40, CMD lactate >4 mmol/L, intraventricular
hemorrhage (IVH) sum score >5 (median), presence of
intracerebral hematoma (ICH) on admission head CT and
perilesional probe location (Table 2). In the multivariate
model, higher CMD [K+] was significantly associated with
CMD LPR >25, CMD LPR >40, CMD lactate >4 mmol/L and
presence of ICH after adjusting for probe location and CPP
≤70mmHg (Table 3).
There was no association between brain metabolic and
physiological parameters and higher plasma [K+] (data
not shown).Cerebral microdialysate potassium concentration, brain
metabolism and outcome
The percentage of episodes of higher CMD [K+] (above
the median of 3 mmol/L) was higher in patients with
poor 3-month outcomes (71% (50% to 78%)) compared toerebral microdialysate concentrations. [K+] = Potassium concentration;
Figure 2 Potassium concentration in cerebral microdialysate
depending on functional outcome. Percentage of episodes of
potassium concentration ([K+]) above 3 mmol/L in cerebral
microdialysate (CMD) between patients with modified Rankin Scale
(mRS) scores ≤4 and those with mRS scores >4 three months after
ictus. Bars represent median and IQR. **P = 0.006.
Table 2 Factors associated with higher potassium
concentration in cerebral microdialysatea
CMD [K+] >3 mmol/L
Independent variables OR (95% CI) P-value
Age > 56 yr (median) 0.7 (0.3 to 2.0) 0.548
Hunt and Hess grade >3 2.1 (0.8 to 5.5) 0.141
APACHE II score > 18 (median) 1.6 (0.6 to 4.4) 0.322
Perilesional CMD probe location 3.4 (1.3 to 8.9) 0.010
Modified Fisher scale = 4 1.4 (0.5 to 3.8) 0.487
IVH sum score >5 (median) 3.0 (1.1 to 8.1) 0.026
Intracerebral hematoma 3.1 (1.2 to 8.1) 0.022
Bicaudate index >0.2 1.2 (0.4 to 3.4) 0.764
Admission GCE 0.6 (0.2 to 1.9) 0.425
Delayed cerebral infarction 1.4 (0.4 to 5.4) 0.623
ICP >20 mmHg 2.8 (1.0 to 8) 0.058
CPP ≤70 mmHg 1.8 (0.8 to 3.8) 0.128
PbtO2 < 20 mmHg 1.7 (0.6 to 2.9) 0.422
CMD lactate >4 mmol/L 4.2 (2.0 to 8.7) 0.0001
CMD pyruvate <119 μmol/L 0.7 (0.3 to 1.4) 0.267
CMD LPR >25 3.6 (1.4 to 9.2) 0.008
CMD LPR >40 5.1 (2.5 to 10.1) <0.0001
CMD glucose <0.7 mmol/L 0.9 (0.5 to 1.7) 0.719
CMD glutamate >10 μmol/L 2.1 (0.9 to 5.0) 0.099
aAPACHE II = Acute Physiology and Chronic Health Evaluation II; CI = Confidence
interval; CMD = Cerebral microdialysate; CPP = Cerebral perfusion pressure;
GCE = Generalized cerebral edema; ICP = Intracranial pressure; IVH= Intraventricular
hemorrhage; [K+] = potassium concentration; LPR = Lactate/pyruvate ratio;
OR = Odds ratio; PbtO2 = Brain tissue oxygen tension. Higher CMD [K
+] was
defined as values above the median.
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(Figure 2). To verify the association between poor outcome
and higher CMD [K+] and CMD LPR >40, generalized esti-
mation equation models were calculated with day after
SAH as the factor and age and admission Hunt and Hess
grade as the covariates. These adjusted models showedTable 3 Multivariate model of factors associated with
higher potassium concentration in cerebral
microdialysatea
CMD [K+] >3 mmol/L
Independent variables OR (95% CI) P-values
IVH sum score >5 (median) 2.2 (0.8 to 6.2) 0.124
Intracerebral hematoma 3.3 (1.3 to 8.2) 0.013
ICP >20 mmHg 2.7 (1.0 to 7.3) 0.058
CMD lactate >4 mmol/L 4.3 (2.1 to 8.7) <0.0001
CMD LPR >25 5.2 (1.8 to 15.0) 0.002
CMD LPR >40 4.4 (2.2 to 8.8) <0.0001
aCI = Confidence interval; CMD = Cerebral microdialysate; ICP = Intracranial
pressure; IVH = Intraventricular hemorrhage; LPR = Lactate/pyruvate ratio;
OR = Odds ratio. Each model was adjusted for probe location and cerebral
perfusion pressure ≤70 mmHg. Higher CMD [K+] was defined as value
above the overall median.a statistically significant effect of higher CMD [K+] and
CMD LPR >40 on poor functional 3-month outcomes
(P < 0.01) (Figure 3).Discussion
The main findings of this study suggest that higher
CMD [K+] levels are associated with brain metabolic dis-
tress and poor functional outcomes and that CMD [K+]
levels do not correlate with corresponding plasma [K+]
levels. The poor correlation between brain extracellular
and plasma [K+] suggests integrity of the electrical bar-
rier [16] and a primarily brain parenchymal origin of
CMD [K+]. Brain extracellular K+ accumulation in the
subcortical brain regions may be explained secondarily
to membrane breakdown [3-5] and erythrocytolysis [2]
(Figure 4). In line with that explanation, we found higher
CMD [K+] in perilesional brain regions and an association
with the presence of SAH related intraparenchymal
hematoma. These findings suggest diffusion of extracellu-
lar K+ through the interstitial spaces with [K+] gradient
from intracerebral hematoma and infarction to adjacent
and more distant brain areas. Furthermore, although
not statistically significant, almost all episodes of ICP
>20 mmHg had CMD [K+] above the median, supporting
the association between high CMD [K+] and cell damage.
In this study, we may have missed transient brain extra-
cellular K+ elevations because of our hourly sampling
method, whereas a rapid-sampling microdialysis technique
may detect rapid changes in brain extracellular [K+] [4].
Higher CMD [K+] was associated with elevated CMD
lactate levels and brain metabolic distress. This associ-
ation may be explained by the phenomenon of inverse
neurovascular coupling triggered by excessive extracellu-
lar [K+], leading to vasoconstriction with consecutive
regional hypoperfusion and metabolic derangement [25].
Moreover, excessive extracellular K+ has been recognized
Figure 3 Daily potassium concentrations and lactate/pyruvate ratio in cerebral microdialysate and functional outcome. Daily potassium
concentration ([K+]) and lactate/pyruvate ratio in cerebral microdialysate (CMD) of 28 aneurysmal subarachnoid hemorrhage patients stratified by
3-month modified Rankin Scale scores (3 m mRS) ≤4 (open boxes) and >4 (filled boxes) (mean ± SEM). **P < 0.01. In patients with poor functional
outcome, there is a peak CMD [K+] on the first day, and, later, on the tenth day after ictus. This evolution of CMD [K+] further supports the relationship
between brain extracellular (EC) K+ levels and early and secondary brain tissue injury.
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of cortical spreading depolarization (CSD) which, under
a pathological environment, can lead to spreading is-
chemia [26-29]. Our study investigates CMD [K+] and
cerebral metabolism of the subcortical white matter.
Spreading depolarization as a cortical phenomenon isFigure 4 Interaction diagram between potential causes for and conse
Interaction diagram between brain events that may lead to cerebral extrac
relationship between higher cerebral microdialysate (CMD) K+ concentratio
based on previously published literature (full line) and our findings (dashedhighly energy-demanding and has been shown by previous
researchers to cause neuronal dysfunction in subcortical
areas of the brain in rodent models [12,30-32]. In patients
with aSAH, there is growing evidence that CSDs occur
abundantly [33]. Investigators in a recent clinical study
demonstrated that clustered CSDs are associated with aquences of cerebral extracellular potassium accumulation.
ellular (EC) potassium accumulation and an explanation model for the
n [K+] and cerebral metabolic distress and poor functional outcome,
line). For further description, see Discussion text.
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CMD lactate and CMD LPR, which they measured by
cerebral microdialysis [34] (Figure 4).
We found an independent association of both higher
CMD [K+] and LPR with poor 3-month outcomes. Both
parameters may be interpreted as surrogate markers for
brain tissue injury after aSAH. According to this hypoth-
esis, hemorrhage load and secondary brain injury are asso-
ciated with disturbed brain metabolism and poor outcome
[35-38] (Figure 4).
The potential toxic effect of K+ load in aSAH patients
raises an important issue for neuroprotective strategies
that may embrace buffering or release of excessive extra-
cellular K+. Clinical management can rest on avoiding
further K+ accumulation by maintaining balance be-
tween energy supply and demand in order to sustain the
performance of the Na+/K+ pump for neuronal repolari-
zation [39,40] and K+ clearance by glial cells [41].
Our study has several important limitations. (1) Only
poor-grade aSAH patients observed at a single center are
represented in this study. This may have introduced a selec-
tion bias restricting the generalizability of our data to the
whole aSAH patient population. (2) No causative association
between higher CMD [K+] and brain metabolism and patient
outcome can be made on the basis of observational data.
This study should be considered a pilot study conducted es-
sentially to further elucidate pathophysiological mechanisms
of secondary brain injury in patients with aSAH and to gen-
erate hypotheses based on our findings. (3) The low time
resolution of K+ measurements in our study may have intro-
duced a washout effect, which causes underestimation of
peak [K+]. The perfusion fluid used for cerebral microdialysis
contained K+ in its composition. Nevertheless, the high re-
covery rate for K+ found in the in vitro analysis suggested
free diffusion of K+ with little obvious influence of the perfu-
sion fluid K+. Therefore, CMD [K+] may be interpreted as an
approximation of real [K+] of the brain extracellular space.
(4) Our approach of taking samples daily for measurement
cannot be used to assess the dynamics between brain ionic,
metabolic and physiological homeostasis and simply focus
on transversal relationships between these parameters.
Despite our study’s limitations, it addresses the associ-
ation between brain extracellular [K+] with its systemic
correlate and brain homeostasis in poor-grade aSAH
patients. Moreover, our method proved to be feasible for
bedside analysis of K+ in the severely injured brain. Future
development and implementation of CMD point-of-care
analytical methods seems to be necessary for a complete
understanding pathophysiologic mechanisms of secondary
brain injury after human aSAH.
Conclusions
The findings of our pilot study suggest that higher CMD
[K+] can be measured and may serve as a surrogatemarker for brain injury in poor-grade aSAH patients.
Further studies are needed to elucidate the relevance of
interstitial K+ levels in the pathophysiology of secondary
brain injury after aSAH.
Key messages
 Higher K+ levels in the extracellular space of the
subcortical white matter may serve as a biomarker
for brain tissue injury in poor-grade aneurysmal
subarachnoid hemorrhage patients.
 Work done in experimental models suggests that
elevated K+ levels in the extracellular space can
drive secondary brain injury after a subarachnoid
hemorrhage. Further human studies are needed to
confirm this hypothesis.
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